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Keywords: Heart Failure; Quality and Outcomes; Thrombosis; Warfarin Both American 1,2 and European 3 guidelines for the management of heart failure (HF) recommend anticoagulation for select HF patients, such as those with atrial fibrillation (AF) to prevent thromboembolism. In this setting, warfarin remains a common choice for anticoagulation, necessitating periodic monitoring of the international normalized ratio (INR) to adjust dosage. In patients on warfarin,
high quality of anticoagulation, as measured by the average time in therapeutic range (TTR), is associated with less thromboembolic event such as stroke or myocardial infarction. 4, 5 Previously using the data of patients with HF with reduced ejection fraction (HFrEF) and sinus rhythm from the Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) trial 6 , we have demonstrated that patients on warfarin with high TTR is associated with improved net clinical benefit compared both with patients on warfarin with low TTR and patients on aspirin only. 7 Unlike patients with AF, however, knowledge who tend to have a better anticoagulation among HFrEF patients is limited despite of high incidence of thrombosis among this population. We therefore undertook the present analysis of HFrEF patients enrolled in the WARCEF trial 6 to investigate the association between HF severity and TTR.
METHODS
The protocol of the randomized, double-blinded WARCEF trial (http://www.ClinicalTrials.gov Trial Reg no. NCT00041938) has been described previously. 6 Briefly, participants with LVEF ≤ 35% who were in sinus rhythm were randomized to receive warfarin or aspirin. Additional eligibility criteria included age ≥ 18 years old, having no contraindications to warfarin, having a modified Rankin score of ≤ 4, and on evidence-based heart failure medications (beta-blocker, angiotensin-converting enzyme The mean follow-up time was 3.5 ± 1.8 years. Institutional Review Boards at the coordinating centers for all sites approved the study, and all participants provided informed consent.
For this analysis, we included participants from the warfarin arm of the WARCEF trial only. Of these, 75 were excluded because they either had follow-up time less than six weeks or had a continuous
interruption of warfarin therapy after six weeks and therefore had missing TTR throughout the study.
The final study sample thus included 1,067 participants.
Assessment of TTR in WARCEF participants was described previously 6, 7 . Briefly, we assumed that any change between two consecutive INR measurements takes place linearly over a 5-day period. For the time period between two consecutive INR measurements, we imputed INR backwards using the INR value of the second measurement until five days after the first measurement. Then we imputed the first five days using linear interpolation of these two INR values. 8 As an example, if the measured INR was For this analysis, we considered the rate of HF hospitalizations per year as a marker of HF severity.
An independent end-point adjudication committee adjudicated all outcomes and major adverse events in WARCEF, and HF hospitalizations were defined as hospital admission for HF or hospitalization for which HF was a major contributing factor for admission and which met all of the following criteria:1)
signs and symptoms of HF on admission; 2) admission to the hospital for at least 24 hours, excluding time in an emergency room or observation unit; and 3) the use of intravenous diuretic, vasodilator, or inotropic therapy for the purposes of treating HF. We also considered New York Heart Association (NYHA) functional class as a measure of severity of HF symptoms and exercise capacity, as well as health-related quality of life measured by the Minnesota Living With Heart Failure (MLWHF) questionnaire, which has been shown to be a powerful predictor of morbidity and mortality among HF patients. 10 MLWHF score was categorized in three groups (MLWHF score: 0-23, good; 24-45,
moderate; 45-105, poor quality of life) 11 . Finally, we measured exercise capacity of the participants quantitatively by the distance walked in six minutes.
To address all possible associations between clinical variables and high TTR, we considered all baseline characteristics obtained in the trial (Table 1) Logistic regression models were used to assess the association between the high TTR and clinical/demographic variables. We also used restricted cubic splines in univariable models to check the potential nonlinear association between high TTR and each variable. In all models, the outcome was high TTR. The final multivariable model was built using forward-backward stepwise selection with entry and removal criteria of p = 0.05. Missing values of baseline variables were imputed using means for continuous variables and modal values for categorical variables. For all statistical analyses, a twotailed P < 0.05 was considered significant.
RESULTS
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A N U S C R I P T Relations between HF severity and TTR are depicted in In the multivariable model after the stepwise selection, we found a higher number of HF hospitalization per year, NYHA class III/IV, and each 10-point increase in MLWHF score were independently associated with decreased likelihood of having high TTR ≥ 70%. Other significant predictors of high TTR were location, older age, race/ethnicity, greater weight, smoking status and other antiplatelet medications (as detailed in Table 2) .
The present study demonstrated for the first time that markers of HF severity are associated with TTR.
In our analysis of patients with HFrEF and sinus rhythm enrolled in WARCEF, HF severity were associated with the quality of anticoagulation independent of other important clinical factors. Our results suggest that for patients with HF being considered for warfarin therapy, those with more advanced HF may have more difficulty in achieving high quality of anticoagulation.
Although warfarin titration in HF patients is known to be challenging 12, 13 , there are several potential mechanisms for why HF severity may be an important risk factor for suboptimal TTR. It is possible that patients with more severe HF may have poorer adherence to taking warfarin or to follow-ups for INR.
14 It is also possible that fluctuating volume status with intermittent volume overload from HF can affect intestinal absorption 15 and metabolism of warfarin. For example, HF induced malabsorption of vitamin K or insufficient intake of vitamin K may predispose patients taking warfarin to INR elevations. 16 Likewise, liver impairment due to congestive HF 17 may interact warfarin response because the hepatic enzyme is responsible for oxidative metabolism of warfarin 18 , while also leading to insufficient production of clotting factors and platelets. There may also be an interaction between cardiovascular comorbidities and genetic determinants of warfarin metabolism, such as CYP2C9 and VKORC1
mutations. [19] [20] [21] Further research is needed to clarify these mechanisms.
Previous studies have examined the factors affecting quality of warfarin anticoagulation in patients with AF [22] [23] [24] [25] [26] and identified that the patients with HF were less likely to achieve target INR range. 22, 24 For instance, the SAMe-TT 2 R 2 22 score was developed from the cohort of the AFFIRM (AF Follow-up Investigation of Rhythm Management) trial and externally validated in prospectively recruited 286 patients. They identified following factors were associated with suboptimal warfarin anticoagulation:
female, less than 60 years of age, history of comorbidities such as hypertension, diabetes, coronary artery disease, peripheral arterial disease, congestive HF, stroke, pulmonary disease, liver or renal
A N U S C R I P T 8 disease, medications which have interaction with warfarin such as amiodarone, tobacco use within 2 years and non-white race. Although mixed results have been observed in other studies [22] [23] [24] [25] [26] , younger age, female, and non-white race/ethnicity were consistently associated with unfavorable INR control. Our findings are broadly similar. In our analysis, we confirmed that younger age and non-Hispanic black race/ethnicity were associated with low TTR. Although the specific mechanism of association between older age and warfarin control is unknown, a possible explanation is that older patients tend to have higher medication adherence than younger patients. 27 In contrast to previous studies, female sex was not independently associated with quality of anticoagulation control in our analysis, possibly due to the modest number of female participants in the WARCEF trial (approximately 20%).
For specific HF patients, such as those with AF or with a high risk for cardioembolism, both
American and European current guidelines recommend anticoagulation to prevent thromboembolism.
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Although not directly addressed by our analysis, we suspect that predictors of suboptimal TTR would be similar to patients with HFrEF who have other indications for anticoagulation. Identifying such patients may be useful to determine the optimal target population for the use of direct oral anticoagulants (DOACs) as DOACs have favorable risk-benefit profiles. 28 Given that optimal warfarin anticoagulation may be difficult to achieve especially in patients with more severe HF, our results also affirms the need to assess the effect of DOACs in this population, such as through the ongoing COMMANDER HF trial, which seeks to assess the effectiveness and safety of rivaroxaban in reducing the risk of death, myocardial infarction or stroke in participants with HF and coronary artery disease following an episode of decompensated HF (https://ClinicalTrials.gov/show/NCT01877915).
There are several limitations to address. First, the cross-sectional design of our study limits causal inference for the relationship between the quality of anticoagulation and HF severity. Second, we could not exclude the possibility that a hereditary predisposition contributed to warfarin resistance because we M A N U S C R I P T 9 did not collect the information about genetic polymorphisms. However, the previous randomized trial has shown that baseline genetic testing on sensitivity to warfarin does not affect clinically important outcomes 29 . Third, the generalizability of our study might be limited because the WARCEF population included only HFrEF patients in sinus rhythm. While we expect similar mechanisms to be at play for HF patients in general, generalizability to HFrEF patients with AF will need to be validated in future studies.
Fourth, the standard of care for HF during the WARCEF trial may differ from contemporary practice. It is reassuring that background pharmacological therapy for WARCEF participants are largely similar to the current era though angiotensin receptor-neprilysin inhibitor was not yet available as a treatment option, with >98%, 90%, 60% of patients receiving an ACE inhibitor or ARB, a beta-blocker, or a mineralocorticoid receptor antagonist, respectively. However, potential confounding may remain from unmeasured differences in how heart failure or anticoagulation were managed during the WARCEF era compared to the current one. Fifth, we did not measure the severity of HF by using existing risk scores such the MAGGIC Risk Score 30 , as we did not capture the data elements necessary to calculate such scores.
In conclusion, a higher rate of HF hospitalizations, NYHA class III/IV, and poor quality of life were independently associated with suboptimal warfarin anticoagulation control among HF patients with reduced ejection fraction. These results affirm the need to assess the new approaches, such as direct oral anticoagulants, to prevent thromboembolism in this patient population.
Figure legends 45-105, poor health-related quality of life). 
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The final multivariable model was built using forward-backward stepwise selection with entry and removal criteria of p=0.05.
